An obesity drug deep-dive, and peptides move mainstream - Takeaways - MDSpire

An obesity drug deep-dive, and peptides move mainstream

  • By

  • Allison DeAngelis

  • Elaine Chen

  • Adam Feuerstein

  • June 11, 2026

  • 0 min

Share

  • 1

    The podcast discusses the potential of new obesity medications, particularly experimental peptides, in mainstream medicine.

  • 2

    Sara Talpos reports on peptide BPC-157, highlighting its journey from a Croatian lab to bodybuilding forums and FDA interest.

  • 3

    The episode covers recent obesity data presented at the American Diabetes Association meeting.

  • 4

    A record-breaking IPO in the biotech sector is also featured in the podcast discussion.

  • 5

    Listeners are encouraged to subscribe to 'The Readout LOUD' on various podcast platforms for more insights.

Original Source(s)

An obesity drug deep-dive, and peptides move mainstream

  • by Allison DeAngelis, Elaine Chen, Adam Feuerstein

  • June 11, 2026

Related Content

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?